azd1236
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00767052)
Timeline
Indications
Mechanism of action
- Matrix metalloproteinase 12INHIBITOR
MMP12 inhibitor
- Matrix metalloproteinase 9INHIBITOR
MMP9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd1236
- azd1236
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02604862 | Early Phase 1 (Phase 1) | May 31, 2016 | NHS Lothian, University of Edinburgh |
| NCT00812045 | Phase 2 | Dec 1, 2009 | AstraZeneca, University of Ottawa |
| NCT01007929 | Phase 1 | Oct 1, 2009 | AstraZeneca |
| NCT00758459 | Phase 2 | Sep 1, 2008 | AstraZeneca |
| NCT00758706 | Phase 2 | Sep 1, 2008 | Aarhus University, AstraZeneca |
| NCT00767052 | Phase 1 | Sep 1, 2008 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2008 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| NHS Lothian | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Edinburgh | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1